Αρχική World News Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of... World News Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours Από Ogkologos - 21 Ιουλίου, 2025 520 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TUXEDO-3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Monoclonal Antibodies May Lower Recurrence Risk for Some Early Stage Breast... 2 Φεβρουαρίου, 2022 The Obesity Paradox: It Increases Diabetes Risk But Can Help Cancer... 13 Μαρτίου, 2020 Cancer in My Community: The 3 Ways People Access Cancer Care... 2 Φεβρουαρίου, 2023 New on NCI’s Websites for December 2022 27 Δεκεμβρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Reunión anual de la American Society of Clinical Oncology de 2022:... EMA Grants a Marketing Authorisation for Two Biosimilar Medicines, Bevacizumab Droplet Transmission vs. Airborne… What’s the difference? Protecting Your Skin From the Sun All Year: Why It’s Important...